SNN icon

Smith & Nephew

28.98 USD
+0.41
1.44%
Updated Mar 17, 1:43 PM EDT
1 day
1.44%
5 days
-2.49%
1 month
11.68%
3 months
13.92%
6 months
-6.40%
Year to date
18.77%
1 year
8.66%
5 years
-0.86%
10 years
-13.75%
 

About: Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Employees: 18,000

0
Funds holding %
of 7,372 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)

276% more call options, than puts

Call options by funds: $933K | Put options by funds: $248K

100% more funds holding in top 10

Funds holding in top 10: 1 [Q3] → 2 (+1) [Q4]

26% more first-time investments, than exits

New positions opened: 39 | Existing positions closed: 31

21% more repeat investments, than reductions

Existing positions increased: 82 | Existing positions reduced: 68

2% more funds holding

Funds holding: 207 [Q3] → 211 (+4) [Q4]

0.34% more ownership

Funds ownership: 3.51% [Q3] → 3.84% (+0.34%) [Q4]

13% less capital invested

Capital invested by funds: $953M [Q3] → $826M (-$127M) [Q4]

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target
$27
7%
downside
Avg. target
$27
7%
downside
High target
$27
7%
downside

2 analyst ratings

positive
0%
neutral
100%
negative
0%
Canaccord Genuity
Caitlin Cronin
15% 1-year accuracy
2 / 13 met price target
7%downside
$27
Hold
Maintained
17 Mar 2025
Canaccord Genuity
Kyle Rose
40% 1-year accuracy
2 / 5 met price target
7%downside
$27
Hold
Maintained
26 Feb 2025

Financial journalist opinion

Based on 11 articles about SNN published over the past 30 days

Negative
Proactive Investors
5 days ago
Smith & Nephew falls after downgrade by leading investment bank
Shares in Smith & Nephew PLC (LSE:SN) fell 2% after UBS downgraded stock in the med-tech firm to 'neutral' from 'buy' on valuation grounds. The price target remains at £12.50.
Smith & Nephew falls after downgrade by leading investment bank
Neutral
GlobeNewsWire
6 days ago
Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will feature the latest advancements in Orthopaedic Reconstruction at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:
Smith+Nephew to showcase advanced Orthopaedic Reconstruction technologies for Robotics, Knees, Hips, and Shoulders at AAOS 2025
Neutral
GlobeNewsWire
1 week ago
Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces it will showcase the latest advancements in Sports Medicine for joint repair at the American Academy of Orthopaedic Surgeons Annual Meeting in San Diego this week. Some of the highlighted technologies will include:
Smith+Nephew to highlight breakthrough Sports Medicine technologies for joint repair at AAOS 2025
Neutral
GlobeNewsWire
1 week ago
New report confirms Smith+Nephew's OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, is pleased to announce that the latest annual report from the Australian Orthopaedic Association National Joint Replacement Registry (AOANJRR) highlights the exceptional performance of Smith+Nephew's proprietary OXINIUM on highly cross-linked polyethylene. The data indicates that this combination has the highest survivorship rate (94.1%) among all bearing combinations over a 20-year period for total hip arthroplasty (THA).1
New report confirms Smith+Nephew's OXINIUM™ Technology is the best performing bearing surface at 20 years for total hip arthroplasty
Neutral
GlobeNewsWire
2 weeks ago
Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research
The global wound care market size was valued at USD 23.13 billion in 2024 and is projected to reach from USD 24.04 billion in 2025 to USD 32.75 billion by 2033, growing at a CAGR of 3.94% during the forecast period (2025-2033). The global wound care market size was valued at USD 23.13 billion in 2024 and is projected to reach from USD 24.04 billion in 2025 to USD 32.75 billion by 2033, growing at a CAGR of 3.94% during the forecast period (2025-2033).
Wound Care Market Size is Expected to Reach USD 32.75 Billion by 2033, Growing at a CAGR of 3.94%: Straits Research
Neutral
CNBC International TV
2 weeks ago
We are having constructive engagement with activist shareholders, says Smith & Nephew CEO
Deepak Nath, CEO of Smith & Nephew discusses spin offs, navigating the China market, and the medical tech firm's full-year earnings for 2024.
We are having constructive engagement with activist shareholders, says Smith & Nephew CEO
Neutral
Seeking Alpha
2 weeks ago
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Smith & Nephew plc (SNN) Q4 2024 Earnings Call Transcript
Positive
Proactive Investors
2 weeks ago
Smith & Nephew sees turnaround plan kicking in as profit grows
Smith & Nephew PLC has said 2025 should show its transformation plan kicking in despite ongoing woes in China after improving trading over the last year. Revenue climbed 4.7% to US$5.8 billion in the year to December 31, the medical equipment maker said Tuesday, aiding an 8.2% increase in trading profit to US$1.1 billion.
Smith & Nephew sees turnaround plan kicking in as profit grows
Positive
Reuters
2 weeks ago
UK's Smith+Nephew beats annual profit expectations
Smith+Nephew beat analysts' expectations for annual sales and profit on Tuesday, as a recovery in its U.S. knee and hip implant business, along with cost cuts, helped the medical products maker offset the impact of weak demand from China.
UK's Smith+Nephew beats annual profit expectations
Negative
Proactive Investors
3 weeks ago
Smith & Nephew has to impress in results after ringing warning bell
Smith & Nephew PLC has left itself with the mounting task of having to give investors something to cheer about after ringing the warning bell last time out. Ahead of full-year figures on Tuesday, 25 February, AJ Bell analysts noted the medical equipment maker flagged it and chief executive Deepak Nath needed to reassure.
Smith & Nephew has to impress in results after ringing warning bell
Charts implemented using Lightweight Charts™